Cynata Therapeutics Ltd has released a press release.
Trading Halt
Filed with ASX ·
On 6ix: 6ix.com/news/trading-halt-661
6ix hasn’t read this filing yet.
Cynata Therapeutics Limited on 6ix
Earlier from Cynata Therapeutics
- Cynata Receives $1.88m R&D Tax Incentive Refund
- Study of Cymerus MSCs in Pulmonary Fibrosis Published
- Cynata to Acquire IP from Tekcyte
- Further GvHD Clinical Data Published in Nature Medicine
- DFU Clinical Trial Enrolment Complete
Later from Cynata Therapeutics
- Demonstrated Safety & Efficacy in DFU Clinical Trial
- Cynata secures commitments for $8.1m institutional placement
- First Kidney Transplant Trial Patient Treated
- Quarterly Activity Report & Appendix 4C
- Publication comparing Cymerus MSCs to other MSCs
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics